Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

Maria Svensson, MD
Published: Tuesday, Mar 27, 2018



Maria Svensson, MD, Lund University, discusses the impact of determining PD-L1 status for patients with esophageal and gastric adenocarcinoma.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the PD-1 receptor as it relates to mismatch repair (MMR) status.

It is important to find good biomarkers for prognosis, explains Svensson. Patients with high PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had prolonged survival. In this study, the prognostic value was evident in MMR-proficient tumors. PD-L1 expression and MMR status can be useful in the clinic in the future for different settings, adds Svensson.
 
SELECTED
LANGUAGE


Maria Svensson, MD, Lund University, discusses the impact of determining PD-L1 status for patients with esophageal and gastric adenocarcinoma.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the PD-1 receptor as it relates to mismatch repair (MMR) status.

It is important to find good biomarkers for prognosis, explains Svensson. Patients with high PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had prolonged survival. In this study, the prognostic value was evident in MMR-proficient tumors. PD-L1 expression and MMR status can be useful in the clinic in the future for different settings, adds Svensson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x